Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Suchergebnisse filtern
Datenmodelle auswählen

Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

67 Suchergebnisse.

Bladder Cancer NCT01224665 - Pre-Randomization Off-Study Form Bladder Cancer #52060 S1011 NCT01224665

- 24/03/2015 - 1 Formular, 5 Itemgruppen, 24 Datenelemente, 1 Sprache

Itemgruppen: Header Module, Treatment Information, Off Treatment Reason, Additional Treatment, Vital Status

S1011 Pre-Randomization Off-Study Form (#52060) Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer NCT01224665 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9399F2B7-7E68-06C0-E040-BB89AD436952

Eligibility Bladder Cancer NCT01954173

- 18/08/2019 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Adjuvant Radiation for High Risk Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01954173

Eligibility Bladder Cancer NCT00389155

- 04/10/2017 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00389155

Eligibility DRKS00004052 NCT00661609 Bladder Cancer - Eligibility Advanced Bladder Cancer NCT00661609

- 17/09/2021 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache

Itemgruppen: Inclusion criteria, Exclusion criteria

Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See http://clinicaltrials.gov/ct2/show/record/NCT00661609

Bladder Cancer NCT00014534 Follow-Up - CALGB: 90104 New Primary Cancer Form - 2169482v3.0 - CALGB: 90104 New Primary Cancer Form

- 09/01/2015 - 1 Formular, 1 Itemgruppe, 16 Datenelemente, 1 Sprache

Itemgruppe: CCRR MODULE

CALGB: 90104 New Primary Cancer Form Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1B57B8-FFB5-70FA-E034-0003BA12F5E7

Bladder Cancer CALGB 90104 NCT00014534 - Chemotherapy Dose Form Bladder Cancer (CALGB 90104)

- 25/07/2015 - 1 Formular, 1 Itemgruppe, 26 Datenelemente, 1 Sprache

Itemgruppe: Chemotherapy Dose Form

CALGB: 90104 Chemotherapy Dose Form Combination Chemotherapy in Treating Patients With Bladder Cancer NCT00014534 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1C0B11-7B76-737C-E034-0003BA12F5E7

Eligibility DRKS00010322 NCT00246974 Bladder Cancer - Eligibility

- 11/12/2013 - 1 Formular, 2 Itemgruppen, 7 Datenelemente, 2 Sprachen

Itemgruppen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00246974

Registration Bladder Cancer CALGB 90104 NCT00014534

- 30/07/2015 - 1 Formular, 2 Itemgruppen, 34 Datenelemente, 1 Sprache

Itemgruppen: Initial Patient Consent for Specimen Use, Registration

Registration Worksheet - 2169258v3.0 CALGB 90104 Registration Worksheet Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1B0241-438C-6AC6-E034-0003BA12F5E7

Follow-Up Form Bladder Cancer (NCT00942331)

- 08/01/2015 - 1 Formular, 8 Itemgruppen, 44 Datenelemente, 1 Sprache

Itemgruppen: Header, Vital Status, Treatment Status, Disease Assessment, Measurable Disease Response, Notice of New Primary, Long-Term Toxicity, Non-Protocol Therapy

CALGB 90601: Follow-Up Form Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6591C082-D8C1-EC1C-E040-BB89AD43479B

Eligibility DRKS00004052 NCT00661609 Advanced Bladder Cancer - Eligibility

- 06/12/2013 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 2 Sprachen

Itemgruppen: Inclusion Criteria, Exclusion Criteria

The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer

On-Study Form Bladder Cancer NCT00014534 CALGB-90104

- 21/08/2015 - 1 Formular, 3 Itemgruppen, 61 Datenelemente, 1 Sprache

Itemgruppen: Muscle Invasive Bladder Disease: Prior Treatment Affecting the Bladder, Prior Therapy Date, CCRR MODULE

On-Study Form Bladder Cancer NCT00014534 CALGB-90104 NCT00014534 NCI Cooperative Group On-Study Form-Revised (CALGB-90104) Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1B6E9C-942E-7181-E034-0003BA12F5E7

Treatment Form Bladder Cancer CALGB 90601 NCT00942331

- 25/07/2015 - 1 Formular, 6 Itemgruppen, 46 Datenelemente, 1 Sprache

Itemgruppen: Header, Clinical Data, Gemcitabine, Cisplatin, Bevacizumab/placebo, Gemcitabine/Cisplatin

CALGB 90601: Treatment Form Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=65402ABE-C4AA-902C-E040-BB89AD435D5A

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.